bms-906024
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 3, 2011 (NCT01292655)
Timeline
Indications
Mechanism of action
- Gamma-secretase subunit APH-1AINHIBITOR
APH1A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- al101
- bms-906024
- bms-906024
- bms-906024
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03691207 | Phase 2 | Oct 31, 2018 | Ayala Pharmaceuticals, Inc, |
| NCT01653470 | Phase 1 | Oct 12, 2012 | Bristol-Myers Squibb |
| NCT01363817 | Phase 1 | Sep 28, 2011 | Bristol-Myers Squibb |
| NCT01292655 | Phase 1 | Mar 3, 2011 | Bristol-Myers Squibb |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 3 | 3 | 1 | 2011 |
| Ayala Pharmaceuticals, Inc, | For profit | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1